Welcome to our dedicated page for ChromaDex Corporation news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on ChromaDex Corporation stock.
ChromaDex Corporation (NASDAQ: CDXC) is a pioneering global nutraceutical company dedicated to enhancing healthy aging through scientific advancements. The company's mission revolves around improving the way people age by focusing on the potential of nicotinamide adenine dinucleotide (NAD+), a critical coenzyme in metabolic processes that declines with age.
ChromaDex's team of scientists partners with renowned universities and research institutions worldwide to explore and develop innovative, science-based ingredients. Their flagship product, Tru Niagen®, is a supplement that features Niagen® (nicotinamide riboside), an NAD+ precursor aimed at promoting better aging. Alongside Tru Niagen®, ChromaDex's product portfolio includes PteroPure® (pterostilbene), PureEnergy® (a caffeine-pterostilbene co-crystal), and Anthorigin™ (anthocyanins).
The company operates through three primary segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The majority of ChromaDex's revenue is generated from its Consumer Products segment, driven by the popularity and efficacy of Tru Niagen®.
ChromaDex's commitment to scientific research is evident in its numerous collaborations with academic institutions. These partnerships aim to uncover the full potential of NAD+ and other beneficial compounds to develop products that support health and longevity.
The company's stock is publicly traded on NASDAQ under the symbol CDXC. For more information on ChromaDex, visit their website at www.chromadex.com, follow them on Twitter @chromadex, or like their Facebook page here.
Recent Achievements and Current Projects:
- Continued research and development into NAD+ and its related compounds.
- Expansion of Tru Niagen® into new markets globally.
- Ongoing partnerships with leading universities and research institutions.
- Innovative new product launches aimed at further promoting healthy aging.
ChromaDex Corp. (CDXC) reported record revenue of $21.0 million for Q4 2022, an 18% increase year-over-year. Tru Niagen® sales rose by 14% to $16.1 million. Despite a net loss of $1.4 million, adjusted EBITDA improved to a profit of $0.4 million, reflecting operational efficiency. Full year sales totaled $72.0 million, up 7%, driven by e-commerce growth. The company signed a long-term agreement with Nestlé Health Science and received two new U.S. patents. Looking ahead, ChromaDex expects at least 10% revenue growth in 2023 amidst economic uncertainty, while projecting stable gross margins and reduced administrative expenses.
ChromaDex Corp. (NASDAQ:CDXC) announced its participation at the 35th Annual ROTH Capital Partners Conference in Dana Point, CA. CEO Rob Fried will present in a fireside chat on March 13th at 11:00 a.m. PT, highlighting ChromaDex's dedication to healthy aging and its pioneering research on NAD+.
The event, one of the largest for small-cap companies, includes presentations, Q&A sessions, and one-on-one meetings with investors. ChromaDex has been recognized as a distinguished healthcare sector presenter.
For more details, visit www.chromadex.com.
FAQ
What is the current stock price of ChromaDex Corporation (CDXC)?
What is the market cap of ChromaDex Corporation (CDXC)?
What is ChromaDex Corporation's main focus?
What is Tru Niagen®?
How does ChromaDex generate most of its revenue?
On which stock exchange is ChromaDex traded?
What are some of ChromaDex's other products?
Who are ChromaDex's research partners?
What is NAD+?
Where can I find more information about ChromaDex?
Does ChromaDex offer services apart from consumer products?
How is ChromaDex contributing to healthy aging research?
